As a recent example, a therapeutic Qβ-based VLP displaying islet amyloid polypeptide (IAPP) on its surface was able to induce potent antibodies against IAPP aggregates in islets of vaccinated mice, causing a delayed onset of type II diabetes in this murine disease model (25). The gene discussed is IAPP; the disease is type 2 diabetes mellitus.